Jiangxi Biological, received the China Securities Regulatory Commission filing notice, and may soon have a hearing for listing in Hong Kong.

Ask AI · How can Jiangxi Biotech’s technological advantages support a listing in Hong Kong?

On April 30, 2026, the International Cooperation Department of the China Securities Regulatory Commission issued a filing notice titled “Full Circulation” regarding the overseas offering and listing of Jiangxi Biotech Products Research Institute Co., Ltd. and the “full circulation” filing for domestic unlisted shares (Guo He Han [2026]935).
**

Pursuant to the filing matters, Jiangxi Biotech may issue no more than 10,432.15 million shares of overseas listed ordinary shares. The company’s 47 shareholders plan to convert a total of 270,855,819 domestic unlisted shares they hold into overseas listed shares, which will then be listed and traded on the Hong Kong Stock Exchange.

Jiangxi Biotech submitted its IPO prospectus to the Hong Kong Stock Exchange on October 26, 2025, with China International Capital Corporation and China Merchants Securities International serving as joint sponsors.

Jiangxi Biotech, as China’s largest provider and exporter of human tetanus antitoxin (human TAT), and a full-industry-chain integrated antiserum platform company, has built a solid market position domestically and internationally through over 50 years of professional expertise in the research, production, and sales of antiserum products. The company’s human TAT has been included as a Class A national medical insurance product, listed in the National Basic Medical Insurance Drug Directory and the National Emergency (Rescue) Drug List, enjoying high market recognition and the advantage of full reimbursement under medical insurance.

According to Frost & Sullivan’s data:

• Jiangxi Biotech is one of the few antiserum companies in China and globally that has achieved full industry chain integration, with end-to-end capabilities across the entire value chain—covering animal breeding, antigen development and testing, host animal immunization, immune plasma collection, and antibody purification and formulation. Jiangxi Biotech’s animal immunization and antiserum preparation processes are comprehensive, mature, and comparable to world-leading levels.****

• ******Jiangxi Biotech is the only company in the world that develops antiserum products using recombinant proteins,******mRNA, and serum-free antigens;

• Jiangxi Biotech is the first and only company in China to use preservative-free packaging and Pasteur virus removal/inactivation technology forhuman TAT;

• ****Jiangxi Biotech has China’s largest GMP-standard equine breeding and immune plasma collection facilities, ensuring a stable supply of high-quality raw materials for antiserum and serum-derived products. The company has established internal production facilities for both human and veterinary medicines to ensure scalability, quality, and cost efficiency.

Jiangxi Biotech has submitted its IPO prospectus and plans to list in Hong Kong, with China International Capital Corporation and China Merchants Securities International serving as joint sponsors.

Jiangxi Biotech IPO prospectus link:

https://www1.hkexnews.hk/app/sehk/2025/107806/documents/sehk25102600195_c.pdf